Geographic atrophy is an advanced form of age-related macular degeneration characterized by progressive and irreversible retinal tissue loss leading to central vision decline. It is often referred to as atrophic AMD or advanced dry AMD. Disease progression substantially affects reading, face recognition, and other daily functions.
Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.
Ocugen reported Phase 2 data for its geographic atrophy gene therapy OCU410 showing 31% lesion growth reduction versus control. The company plans Phase 3 initiation in Q3 2026 and maintains its goal of three BLA filings in three years. Shares fell 11.48% following the data release which trailed earlier interim results.
Ocugen will host a conference call on March 4, 2026 at 8:30 a.m. ET to discuss fourth quarter and full year 2025 financial results and provide a business update, with a pre-market earnings announcement the same day.
Belite Bio announced preliminary Q4 2025 results and plans to submit an NDA for tinlarebant in Q2 2026 following positive Phase 3 trial results. BioArctic reported record financial results with operating profit exceeding SEK 1.2 billion for 2025. Recordati delivered strong preliminary full-year 2025 results despite FX headwinds.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602127 |
Safety and Efficacy Study of Novel Gene Therapy AGX-08 for Geographic Atrophy |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07594236 |
Phase 1 Study of C.001 in Retinal Degeneration |
RECRUITING | PHASE1 |
| NCT07570355 |
Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy |
NOT_YET_RECRUITING | NA |
| NCT07556406 |
Central micrOperimetry and Radial OCT Evaluation in Geographic Atrophy (CORE-GA): a Prospective Pilot Study |
RECRUITING | |
| NCT07529041 |
Real-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmic Imaging Diagnostic Quality |
ENROLLING_BY_INVITATION | NA |
| NCT07433088 |
Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints |
NOT_YET_RECRUITING | NA |
| NCT07428798 |
Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration |
COMPLETED | NA |
| NCT07424235 |
Evaluating the Relationship Between Function and Structure Using Data From a GA Natural History Cohort |
COMPLETED | |
| NCT07298174 |
Wide Field OCTA in Ocular Diseases |
NOT_YET_RECRUITING | |
| NCT07215234 |
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration |
RECRUITING | PHASE1/PHASE2 |
